Metrics cut 1
- Dhejaj 2 MCC expansion commissioning timeline slipped to Q2 FY28 (from earlier Q1 FY28 guidance)
Event Participants
Executives
2 Amit Raj Sinha, O. Subbarami Reddy, Vivek Kumar
Analysts
8 Amit Mora, Ankit Gupta, Ankur, Darshil Jhaveri, Dasu Goenka, Deepak Chokhani, George, Gautam Karva, Nalin Shah, Rahul Dasani, Rupesh Tatiya
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Operating Income | ₹121.27 crores | Q1 FY27; seasonal softness; QoQ improvements expected through the year |
| EBITDA | ₹16.5 crores (13.6% margin) | Margins expected to expand to 18% full-year as revenue ramps with fixed costs constant |
| Net Profit | ₹8.14 crores (PAT margin: 6%) | Lower due to Q1 revenue base; MAT liability incurred despite carried-forward losses |
| MCC Segment Revenue | ₹82.74 crores | Average realization ₹241.36/kg vs ₹216/kg in Q4 FY26 (+11.7% QoQ); volume ~3,400 MT |
| API Segment Revenue | ₹21.68 crores | Ramp-up on track; guided ₹100-110 crores for FY27; new high-margin molecules launched |
| O&M Segment Revenue | ₹13.06 crores | Steady, scalable contributor; limited commentary provided |
| MCC Capacity Utilization | 76.8% (company average) | Per-unit: H unit 76.5%, Sigma unit 77.16%; to improve QoQ via debottlenecking |
| MCC Realization | ₹241.36/kg | Up from ₹216/kg in Q4 FY26; continued QoQ improvement expected |
| Receivables Days | ~93-94 days | Management targeting reduction to ~90 days then 75-80 days |
Geographic & Segment Commentary
MCC (Microcrystalline Cellulose): Export-focused with 53.5% of production exported across 65 countries. Maintained pricing power with realization up 11.7% QoQ despite competitive capacity additions. Lost market share due to ~3,000-6,000 MTPA capacity reduction from Hyderabad facility incident; management expects to regain wallet share once Dhejaj 2 expansion (12,000 MTPA) commissions by Q2 FY28, taking total capacity to 30,000 MTPA. FY25 sales were ~20,000 tons versus current ~14,000 ton run-rate.
CCS (Croscarmellose Sodium): New 1,800-ton facility at Dhejaj SEZ on track for FY28 commissioning. India market estimated at ~$100 million with realizations of $1,200-1,500/ton for premium grades. Targeting 25%+ margins despite importing CMC (key raw material) from China, as cross-selling to existing MCC customers via approved vendor relationships will accelerate adoption. Export-focused strategy with pre-orders already being received. Management rationalizes importing CMC rather than backward integrating given China's lakhs of tons capacity.
API Business: Q1 revenue of ₹21.68 crores with new high-margin molecules (Sparsentan, Bempetide Acid) driving growth. Pipeline supporting CE filing for regulated market expansion. Inventory destocking not an issue per management; targeting ₹100-110 crores FY27 revenue.
HiCell SMCC Nutra (New Product): Launched during the quarter - combination of MCC and magnesium aluminum metasilicate targeting nutraceutical formulations; addresses flowability, compressibility, and processing challenges. Supports strategy of moving up the value chain into differentiated, application-specific excipients.
Company-Specific & Strategic Commentary
Capacity Expansion (Dhejaj 2): 12,000 MTPA MCC capacity on schedule for Q2 FY28 commissioning (slipped from earlier Q1 FY28 guidance); will total 30,000 MTPA cellulose-based capacity. Management expects rapid utilization ramp given 30-year supply chain relationships. Additional debottlenecking initiatives should push current capacity from 18,000 to ~19,600 MTPA.
Insurance Recovery: Property loss assessment completed and submitted; salvage e-auction conducted with additional reports to be submitted within the week. Management expects full claim settlement (with some discount) or ad hoc payment by September 2026. Business continuity insurance of ₹25 crores (₹16.5 crores eligible) expected within 3-4 months, not September.
Product Mix Optimization: Strategy focuses on shifting toward higher-margin co-processed products with realizations of ₹600-700/kg (versus ₹241/kg average for standard MCC). CCS and API molecules positioned to structurally improve blended margins.
Product Mix Optimization: Strategy focuses on shifting toward higher-margin co-processed products with realizations of ₹600-700/kg versus ₹241/kg average. CCS (25%+ margins) and high-margin API molecules positioned to structurally improve blended margins.
Capital Allocation: FY27 CapEx guided over ₹100 crores; FY28 additional ₹150-200 crores. Projects include MCC (₹106 crores), CCS (₹90 crores), plus further capacity expansions (₹50 crores gap). Funding options: term loans (company currently debt-free), preferential equity, or warrants - announcement to follow after finalization.
Product Mix Optimization: Strategy focuses on shifting toward higher-margin co-processed products with realizations of ₹600-700/kg (versus ₹241/kg average for standard MCC). CCS and API molecules positioned to structurally improve blended margins.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (FY27) | ₹650-675 crores | Reaffirmed; Q1 at ₹121.27 crores with QoQ ramp-up expected; management "on track" despite Q1 softness |
| EBITDA Margin (FY27) | ~18% | Implies significant margin expansion from 13.6% Q1; driven by operating leverage on fixed costs, better product mix, and higher realizations |
| API Revenue (FY27) | ₹100-110 crores | New molecules (Sparsentan, Bempetide Acid) and CE filing pipeline supporting growth |
| MCC Capacity Utilization | Target 95-96%+ exit rate FY27 | Debottlenecking from 18,000 to ~19,600 MTPA; product mix changes and scheduling impact utilization |
| Dhejaj 2 MCC Expansion | Commission by Q2 FY28 | Slipped from earlier Q1 FY28 guidance; project team confirmed Q2 FY28; no further delays anticipated |
| CCS Facility | Operational FY28 | 1,800 tons capacity at Dhejaj SEZ; targeting export market with pre-orders received |
| Insurance Claim (Property) | Full/ad hoc settlement by September 2026 | Business continuity claim (₹16.5 crores) separate - expected in 3-4 months |
Risks & Constraints
| Risk | Context |
|---|---|
| Capacity Constraint / Market Share Loss | Current capacity of ~18,000-19,600 MTPA limits ability to serve customers; lost market share due to 3,000-6,000 MTPA capacity reduction from Hyderabad incident. Management expects to regain share post-Dhejaj 2 commission (Q2 FY28) leveraging 30-year customer relationships. |
| Competitive Capacity Additions / Oversupply | Multiple Indian players expanding MCC capacity raises oversupply concerns. Management argues regulatory compliance and quality approvals are real entry barriers, citing Aurobindo's failed CCS/MCC entry. Asia-Pacific demand CAGR of 7-8% and market size projection of $1.4 billion by 2035 cited as demand-side support. |
| Project Execution / Commissioning Delay | Dhejaj 2 MCC expansion slipped from Q1 FY28 to Q2 FY28. Management expressed confidence but acknowledged some slippage risk exists. CCS facility also pending FY28 commissioning. |
| Insurance Claim Uncertainty | Property claim settlement expected with "some discount" by September 2026; if delayed, CapEx funding could be impacted. Company currently debt-free with stated alternatives (term loans, preferential equity/warrants), but previous preferential warrant issuance had forfeiture issues due to logistical problems (holidays). |
| Legal/Regulatory - Hyderabad Incident | Victim compensation: ₹42 lakhs paid per deceased beneficiary (vs ₹1 crore state government announcement); matter before court with potential additional liability. Management has booked full provision for obligation but stated statutory maximum compensation is being examined by court - outcome uncertain. |
Q&A Highlights
MCC Pricing & Competitive Dynamics
- Question: How worried are we about oversupply given capacity expansions? What's driving realization increases? (Rahul Dasani, MAPL)
- Answer: Management noted quality and regulatory compliance are true barriers to entry in MCC, not just capacity. Cited Aurobindo's failed entry into MCC as evidence. Realizations up to ₹241.36/kg from ₹216/kg in Q4 FY26 (~12% QoQ) driven by product mix shift toward premium grades, innovation, and industry consolidation (global #1 player changed hands twice). Market expected to reach $1.4 billion by 2035 with Asia-Pacific CAGR of 7-8%. (Amit Raj Sinha)
Market Share Loss & Recovery
- Question: We've lost market share to local peers - what's the strategy to win back? (Rahul Dasani, MAPL)
- Answer: Market share loss was primarily supply-driven: capacity reduced by 3,000-6,000 MTPA due to the Hyderabad incident. Customers had to qualify alternative suppliers to maintain production. Management expressed confidence in regaining wallet share once capacity returns, citing three decades of customer relationships and 65-country supply chain network. (Amit Raj Sinha)
Revenue & Margin Guidance Reconciliation
- Question: Q1 revenue was ₹121 crores vs ₹160-170 crore quarterly run-rate needed for guidance. Can we still hit ₹650-675 crores? (Rupesh Tatiya, Long Equity Partners)
- Answer: Management reaffirmed guidance with "no change" - Q1 was "as planned" with only small variations. Revenue ramp accelerates from Q2 onward. For margins, fixed costs remain constant while revenue grows, naturally expanding EBITDA margin toward 18% full-year. Exit rates will need to be higher than 18% in H2 to compensate for weak Q1. (Amit Raj Sinha)
Capacity Utilization vs Revenue Guidance Math
- Question: At 75% utilization and ₹241/kg realization, even at 19,600 MT capacity, revenue math doesn't reach guidance - how does it reconcile? (Rupesh Tatiya; Darshil Jhaveri)
- Answer: Management explained that FY25 sales were
20,000 tons (above declared capacity through debottlenecking), and current Q1 volume of ~3,400 MT reflects the plant "turning around" slowly, not demand issues. Product mix shifts cause shutdowns, cleaning validations, and startups that temporarily reduce output. Realizations are increasing QoQ, and some co-processed grades achieve ₹600-700/kg. API (₹100-110 crores) plus O&M (₹50-55 crores) plus Allied/other trades bridge the gap. Debottlenecking will add ~1,600 MT currently. (Amit Raj Sinha)
CCS Market & Margin Potential
- Question: How big is the CCS opportunity, and can we achieve 25%+ margins importing CMC from China? (Ankit Gupta, Bamboo Capital; Rahul Dasani, MAPL)
- Answer: India CCS market ~$100 million with average realizations of $1,200-1,500/ton (premium grades higher). Management confirmed 25%+ margins are achievable even with imported CMC, as chemistry complexity provides pricing power. Backward integration into CMC deemed "futile" given China's lakhs of tons capacity and cost advantage. Cross-selling to existing MCC customers as approved vendor accelerates adoption. Pre-orders already received from export customers. (Amit Raj Sinha)
API Business Ramp-Up
- Question: When will API revenues hit ₹25-30 crores quarterly? What's driving growth? (Rupesh Tatiya)
- Answer: Q1 achieved ₹21 crores; management expects quarter-on-quarter improvement to reach ₹100-110 crores full-year (~₹25-28 crores/quarter average). New high-margin molecules (Sparsentan, Bempetide Acid) driving growth. No inventory destocking issues in benzoic acid (contrasting with peer commentary). (Amit Raj Sinha)
Insurance Recovery & CapEx Funding
- Question: What's the insurance claim status, and will delayed recovery hamper CapEx? (Nalin Shah; Deepak Chokhani; Dasu Goenka)
- Answer: Assessment completed, salvage e-auction done, additional reports being submitted this week. Full claim settlement (with discount) or ad hoc payment expected by September 2026. Business continuity claim (₹16.5 crores eligible of ₹25 crores policy) separate - expected in 3-4 months. Company currently debt-free with multiple funding options (term loans, preferential equity, warrants). Management declined comment on potential capital raise until finalized. (Amit Raj Sinha)
MCC Utilization - Why Not at 100%?
- Question: If FY25 sales were 20,000 tons, why is current utilization only 75%? Is there a supply or demand issue? (Rupesh Tatiya)
- Answer: Neither supply issue nor market share issue - plant turnaround takes time. Product mix changes require shutdowns, cleaning validations, and startups that reduce throughput. Higher-value grades (₹600-700/kg realizations) traded off against pure volume. Management expects Q4 exit run-rate at 95-96%+ of theoretical capacity (which will have expanded via debottlenecking). (Amit Raj Sinha)
Industry Margin Evolution - Structural Change
- Question: Industry margins went from 12-13% (pre-2019) to 20%+ (2019-2026) - what structurally changed? (Rupesh Tatiya)
- Answer: Combination of factors: (1) Industry consolidation - global #1 player changed hands twice; Indian player acquired by European company; (2) Innovation-driven product mix shift - formulators moved from cheaper MCC grades to sophisticated, application-specific grades with better stability and compatibility with complex APIs; (3) This changed average realizations industry-wide, not just capacity utilization. (Amit Raj Sinha)
Victim Compensation & Legal Status
- Question: Have we transferred the full compensation to victims? Is there ongoing litigation? (Dasu Goenka, Individual Investor)
- Answer: ₹42 lakhs paid per beneficiary of deceased. Matter before court - state government announced ₹1 crore but court has called Inspector of Factories and Workmen Compensation Act/PFESI to determine statutory maximum payable. Management has provided in books for entire amount and stated "we hope there will not be any further liability." Declined further elaboration as matter is sub judice. (Amit Raj Sinha)
Key Takeaway
Sigachi Industries reported Q1 FY27 revenue of ₹121.27 crores (EBITDA margin 13.6%, PAT ₹8.14 crores), reaffirming FY27 guidance of ₹650-675 crores revenue and 18% EBITDA margin based on expected QoQ acceleration from Q2 onward. MCC remains the core driver contributing ₹82.74 crores with realization up 11.7% QoQ to ₹241.36/kg, though capacity utilization at 76.8% reflects the gradual recovery from the Hyderabad incident and product mix optimization toward premium grades. Strategic priorities: Dhejaj 2 MCC expansion (12,000 MTPA) commissioning by Q2 FY28, CCS facility (1,800 tons) targeting 25%+ margins with pre-orders from export customers, and API business ramping toward ₹100-110 crores FY27 revenue via new high-margin molecules including Sparsentan and Bempetide Acid. Insurance recovery (~₹25 crores property claim plus ₹16.5 crores business continuity) expected by September-December 2026, with capex of ₹100+ crores FY27 and ₹150-200 crores FY28 funded via debt (company currently debt-free) or potential preferential issuance. Key watch points: ability to regain lost MCC market share post-expansion, execution on margin expansion to 18% from 13.6% Q1 levels, and legal outcome on Hyderabad incident compensation where ₹42 lakhs paid per beneficiary against ₹1 crore state government announcement.